Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3752W HIGH $33.12
Volume
26.90 K
Value Traded
59.96 K
Short % Float
11.06%
+2.27%Week
-2.44%1 Month
-54.31%3 Month
-59.46%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.26 M
EPS (TTM)
-14.59
P/E Ratio
-
Ent. Value
-6.54 M
Total Shares
1.81 M
Float Shares
1.70 M
Insiders
5.84%
Institutions
3.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
APVO Catalyst Timeline
Dated clinical, regulatory and corporate events for Aptevo Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aptevo Therapeutics Inc.
439Total events
11Upcoming
95Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutmipletamigClinical Data
Reported 93% clinical benefit rate in TP53-mutated frontline AML patients
frontline acute myeloid leukemia (AML) with TP53 mutationssource ↗
▲Partnership / LicenseCorporate
50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical programs
oncologysource ↗
▼Equity OfferingCorporate
Niowave makes at-the-market equity investment in Aptevo at closing, initial ownership 7.9%
▲Trial InitiationTrial
First stage of collaboration designed and ready to initiate, targeting Nectin-4 with Actinium-225
solid tumors (Nectin-4 expressing)source ↗
▲Topline ReadoutmipletamigClinical Data
Mipletamig data update in frontline AML: 87% clinical benefit rate, 81% CR/CRi, no CRS
frontline acute myeloid leukemiasource ↗
▲Topline ReadoutmipletamigClinical Data
Reported 87% clinical benefit and 81% remission in 31 evaluable frontline AML patients through Cohort 5
acute myeloid leukemia (AML)source ↗
●Enrollment UpdatemipletamigTrial
Enrollment in Cohort 6 nearing completion
acute myeloid leukemia (AML)source ↗
◆Management ChangeCorporate
Marvin White to retire as CEO and become Executive Chair; Jeff Lamothe to become President and CEO
▲Topline ReadoutmipletamigClinical Data
Updated interim results from 28 evaluable frontline AML patients: 86% clinical benefit rate, 79% CR/CRi, 61% CR, no CRS
frontline acute myeloid leukemiasource ↗
●Management ChangeCorporate
Marvin White transitions to Executive Chair; Jeff Lamothe becomes President and CEO
▲Topline ReadoutmipletamigClinical Data
Interim data for mipletamig in combination with venetoclax and azacitidine in frontline AML
acute myeloid leukemia (AML)source ↗
▼Equity OfferingCorporate
Aptevo entered into $60 million equity line of credit agreement with Yorkville Advisors
▲Runway Guidance UpdateCorporate
Funding runway extended into 2029 with ELOC and cash on hand
▲Topline ReadoutmipletamigClinical Data
89% remission in evaluable frontline AML patients across two trials with mipletamig combination therapy
frontline acute myeloid leukemia (AML)source ↗
▲Safety Data UpdatemipletamigClinical Data
No cytokine release syndrome observed among evaluable frontline AML patients to date
frontline acute myeloid leukemia (AML)source ↗
▼Equity OfferingCorporate
Raised $18.7 million net in Q3 2025 and $4.1 million net since quarter end
◆Oral PresentationmipletamigPresentation
RAINIER trial results to be presented at major medical conference in Q4
acute myeloid leukemia (AML)source ↗
▲Topline ReadoutmipletamigClinical Data
100% remission rate in Cohort 3 of RAINIER trial
acute myeloid leukemia (AML)source ↗
▲Enrollment CompletemipletamigTrial
Cohort 3 enrollment completed
acute myeloid leukemia (AML)source ↗
▲Preclinical PoCAPVO452Preclinical
Preclinical studies show APVO452 effectively kills tumor cells and activates immune system only in presence of tumor cells
prostate cancersource ↗
▲Preclinical PoCAPVO451Preclinical
Early data indicate potent anti-cancer activity for APVO451
solid tumorssource ↗
▲Pipeline PrioritizationCorporate
Expansion of CD3 oncology pipeline to five molecules with addition of APVO452 and APVO451
▲Enrollment CompletemipletamigTrial
Cohort 2 enrollment complete in RAINIER trial
frontline acute myeloid leukemia (AML)source ↗
◆Enrollment UpdatemipletamigTrial
Cohort 3 now enrolling in RAINIER trial
frontline acute myeloid leukemia (AML)source ↗
▲Safety Data UpdatemipletamigClinical Data
No CRS observed in RAINIER trial to date
frontline acute myeloid leukemia (AML)source ↗
▼Equity OfferingCorporate
Raised approximately $4.9 million in April and May 2025 through direct offerings and ATM facility
▼Equity OfferingCorporate
Registered direct offering of 2,324,000 shares at $0.862 per share for gross proceeds of $2.0 million
▼Equity OfferingCorporate
Priced $2.1 million registered direct offering and concurrent private placement at $1.19 per share and warrant
●Preclinical PoCAPVO455Preclinical
Introduced APVO455, a Nectin-4 x CD3 bispecific for solid tumors
solid tumors (bladder, breast, NSCLC, head and neck cancers)source ↗
▲Topline ReadoutmipletamigClinical Data
Mipletamig achieved 85% remission rate in frontline AML across two trials
acute myeloid leukemia (AML)source ↗
●Enrollment UpdatemipletamigTrial
Cohort 2 enrollment nearing completion
acute myeloid leukemia (AML)source ↗
▲Topline ReadoutmipletamigClinical Data
Data from prior expansion study: 4/4 frontline patients achieved remission with triplet combination
frontline acute myeloid leukemia (AML)source ↗
▲Enrollment CompletemipletamigTrial
Cohort 1 enrollment completed; 100% remission within 30 days
acute myeloid leukemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How APVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-03-31 | APVO210 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 94%
Micro Cap(rank 619 of 658)
Percentile Rank
Aptevo Therapeutics Inc. faces pipeline headwinds (20/100), with $81M risk-adjusted pipeline value, led by APVO436 in Acute Myeloid Leukemia (AML) (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APVO436 Small moleculeNCT06634394 | Acute Myeloid Leukemia (AML) | Phase 1 | RECRUITING | 39 | Mar 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every APVO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| mipletamig Orphan | acute myeloid leukemia | 2026-05-13 | clinical benefit rate: 87%; remission rate: 81%; complete remission rate: 65%; blast reduction: 52%Read More | Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Harsanyi ZsoltDirector | Option | 400 400 held | $0.00 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in APVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 5.6 % (-29.1 %) | 27.17 M | 1.76 M |
APVO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How APVO ranks across every disease it competes in
Competitive Position is a premium feature
See how APVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAPVO News
APVOAptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Aptevo Therapeutics is advancing its next-generation trispecific candidate, APVO451, toward clinical development. The company is focusing on optimizing scalable manufacturing processes essential for future human testing, with plans to enter IND enabling studies in the first half of 2027. Trispecific therapies are designed to combine multiple cancer-fighting functions, potentially enhancing treatment efficacy.
Read more →APVO▼ -34.2%on this news
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Aptevo Therapeutics reported a 93% clinical benefit rate for its mipletamig triplet in frontline acute myeloid leukemia (AML) patients with TP53 mutations. This result nearly doubles the historical outcomes for similar patients treated with venetoclax and azacitidine. The mipletamig triplet demonstrated a 79% complete remission rate, highlighting its potential as a promising treatment option in this challenging patient population.
Read more →APVO▼ -13.5%on this news
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aptevo Therapeutics reported significant advancements in its oncology pipeline during Q2 2026, particularly with mipletamig showing promising results in frontline acute myeloid leukemia (AML). The company appointed a new Chief Scientific Officer to strengthen its leadership and secured a $1.5 million grant for APVO451. Additionally, a collaboration with Niowave aims to develop radiopharmaceutical therapies, enhancing Aptevo's strategic position in the market.
Read more →APVO▼ -13.5%on this newsshared move
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Aptevo Therapeutics has successfully closed a warrant inducement transaction, allowing holders to exercise existing warrants for cash, resulting in the issuance of new warrants. The company also completed a private placement, raising approximately $4.5 million. The proceeds will be used for working capital purposes, enhancing its financial position.
Read more →APVO▼ -9.8%on this news· ran to -28% by day 3shared move
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
Aptevo Therapeutics has announced the exercise of existing warrants and a private investment in public equity (PIPE) deal, expected to generate approximately $4.5 million in gross proceeds. The company will issue new warrants in exchange for the exercise of existing warrants and will sell unregistered shares at a price of $4.03 each. The proceeds will be used for working capital.
Read more →APVOAptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Aptevo Therapeutics has announced a new solid tumor strategy with a patent application for a Nectin-4 x PD-L1 dual-targeting backbone. This innovative approach aims to enhance its oncology pipeline and expand therapeutic opportunities. The filing is expected to support various cancer-fighting methods, including radiopharmaceuticals and T-cell engagers, allowing for a more versatile treatment strategy.
Read more →APVOAptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Aptevo Therapeutics has received a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment to advance its trispecific immunotherapy candidate, APVO451. This funding will support IND-enabling studies aimed at enhancing immune activation in solid tumors. The grant is seen as validation of the innovative design of APVO451, which targets nectin-4 and engages T-cells and antigen-presenting cells.
Read more →APVOAptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Aptevo Therapeutics has appointed Dr. Mary J. Janatpour as Senior Vice President and Chief Scientific Officer. With over 25 years of experience in oncology R&D, she will lead the company's research and preclinical development efforts. This appointment comes as Aptevo expands its oncology pipeline and collaborates with Niowave on radiopharmaceuticals.
Read more →APVOAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing 50/50 strategic collaboration will develop up to three radiopharmaceutical programs
Aptevo Therapeutics and Niowave have announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. This partnership, which includes an equity investment from Niowave, aims to leverage Aptevo's multispecific immuno-oncology capabilities alongside Niowave's expertise in radioisotope production. The collaboration focuses on utilizing a clinically validated cancer target, Nectin-4, for novel treatment options aimed at addressing difficult-to-treat cancers. This marks a significant expansion for Aptevo into the growing field of radiopharmaceutical development.
Read more →APVOAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Aptevo Therapeutics provided a business update highlighting the promising performance of mipletamig in frontline acute myeloid leukemia (AML), achieving an 87% clinical benefit rate. The company completed its leadership transition, appointing Jeff Lamothe as CEO. Additionally, Aptevo secured a $60 million equity line to enhance financial flexibility as it advances its clinical programs.
Read more →APVO▼ -7.7%on this news
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Program Enters Final Stage of Dose Optimization
Aptevo Therapeutics has reported promising results from its RAINIER trial, demonstrating an impressive 87% clinical benefit rate and an 81% remission rate among 31 evaluable frontline acute myeloid leukemia (AML) patients. The study, which combines the drug mipletamig with venetoclax and azacitidine, is now in its final stage of dose optimization, with results indicating a strong and consistent profile of clinical activity. The company is on track to complete the trial and select the recommended Phase 2 dose within the year, positioning itself for further advancements in AML treatment. Notably, the absence of cytokine release syndrome highlights the safety profile of mipletamig.
Read more →APVOAptevo Provides State of the Business Report and 2025 Financial Results
Aptevo Therapeutics Inc. reported significant progress regarding its mipletamig therapy, achieving an 86% clinical benefit rate in frontline AML patients without any cytokine release syndrome. The company has expanded its CD3 therapy pipeline and introduced its first trispecific drug candidates. Financially, Aptevo strengthened its capital base with a new $60 million equity line, which is expected to support its operations through 2029. The company is optimistic about the potential of mipletamig to enhance existing AML treatments.
Read more →APVO▼ -22.8%on this news· ran to -34% by day 1
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine
Aptevo Therapeutics has announced new interim data for its drug mipletamig, which shows an 86% clinical benefit rate in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients. Notably, no cases of cytokine release syndrome (CRS) were reported among participants. The results particularly highlight the safety and tolerability of mipletamig, making it a promising candidate to enhance current AML treatments for elderly or unfit patients. The data supports the potential of mipletamig to improve outcomes for those facing poor prognoses in this patient group.
Read more →APVO▼ -10.3%on this news
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond
Aptevo Therapeutics has announced upcoming executive leadership transitions as part of its strategy to support growth and execute long-term objectives. Marvin White will transition from CEO to Executive Chair, while Jeff Lamothe will take over as the new CEO. The leadership change reflects continuity, with all leaders having been part of Aptevo since its inception in 2016. The company aims to leverage its validated technology and expanded pipeline to further patient impact in the oncology space while ensuring strong operational execution.
Read more →APVO▲ +5%on this news
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics has secured a $60 million equity line of credit to enhance its financial flexibility and support its clinical and preclinical pipeline. This funding will allow the company to access capital incrementally and is expected to extend its financial runway into 2029. The company plans to use these funds to advance its multispecific anti-cancer agents, including mipletamig, which has shown promising clinical results.
Read more →APVO▼ -9.4%on this news
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Aptevo Therapeutics has announced a 1-for-18 reverse stock split, effective December 29, 2025. This decision was approved by stockholders and aims to reduce the number of outstanding shares from approximately 18 million to about 1 million. The split is intended to enhance the stock's marketability while maintaining the par value of the shares.
Read more →APVOAptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Aptevo Therapeutics reported its financial results for Q3 2025, highlighting a substantial 89% remission rate in evaluable patients treated with mipletamig for frontline AML. The company introduced two new trispecific T-cell engagers, APVO451 and APVO452, aimed at overcoming immune suppression in solid tumors. Despite a significant rise in cash reserves, the company experienced a net loss of $7.5 million, reflecting increased research and development costs.
Read more →APVOMipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its RAINIER trial evaluating mipletamig for newly diagnosed AML patients unfit for intensive chemotherapy. This first-in-class bispecific antibody displayed a clean safety profile, with no dose-limiting toxicities or cytokine release syndrome observed to date. Additionally, the trial demonstrated that 40% of patients achieved minimal residual disease negative status, indicating a promising pathway for treatment. Cohort 4 is now open for enrollment, potentially expanding mipletamig's clinical impact further.
Read more →APVOAptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX design to target prostat
Aptevo Therapeutics has announced the expansion of its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, designed to target prostate and multiple solid tumor cancers. These new molecules leverage the proprietary ADAPTIR-FLEX platform and build on clinical validation from mipletamig. With the addition of these candidates, Aptevo now offers eight bispecific and trispecific therapeutic candidates, demonstrating its focus on innovation in cancer treatment. The trispecific approach aims to enhance anti-tumor responses while minimizing systemic toxicity.
Read more →APVOAptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Aptevo Therapeutics has reported its financial results for the second quarter of 2025, showcasing significant advancements in its clinical pipeline. The firm’s lead candidate, mipletamig, has demonstrated an impressive 85% remission rate in frontline acute myeloid leukemia (AML) patients. Additionally, Aptevo has expanded its CD3 bispecific portfolio with the introduction of APVO455, targeting multiple solid tumors. Financially, the company secured $15.9 million in funding, extending its cash runway to late 2025, despite reporting a net loss for the quarter.
Read more →About Aptevo Therapeutics Inc.
Headquarters2401 4TH AVE., SEATTLE, WA, 98121
Founded2016
BIOPHARMAWATCH ELITE PLUS
Trade the next APVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime